Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 7/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710048 | 1.00 | TAS2R14 (0.46) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL1363115 | 0.88 | TAS2R14 (0.51) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL1363920 | 0.88 | TAS2R14 (0.51) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL1291418 | 0.88 | TAS2R14 (0.51) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL12140104 | 0.88 | TAS2R14 (0.51) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL15712966 | 0.87 | TAS2R14 (0.47) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL13747842 | 0.87 | AR (0.48) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL1291656 | 0.81 | MEN1 (0.44) | — | |
| SCHEMBL4595644 | 0.81 | TAS2R14 (0.52) | TAS2R14ARCYP2C19ABCB11ALB | |
| SCHEMBL1291330 | 0.81 | AR (0.47) | TAS2R14AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9133182-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2621901-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2012047617-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, GPR119 | TAS2R14 1481/4885AR 1/4885CYP2C19 258/4885 |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | TAS2R14 1481/4885AR 1/4885CYP2C19 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.